821 results about "Respiratory tract infections" patented technology

The present invention relates to therapeutic nanoemulsion compositions and to methods of utilizing the same. In particular, nanoemulsion compositions are described herein that find use in the treatment and/or prevention of infection (e.g., respiratory infection (e.g., associated with cystic fibrosis)), in burn wound management, and in immunogenic compositions (e.g., comprising a Burkholderia antigen) that generate an effective immune response (e.g., against a bacterial species of the genus Burkholderia) in a subject administered the immunogenic composition. Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine), industrial, and research applications.

Methods for formulating immediate and sustained release anti-infectives and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.

Methods for formulating immediate and sustained release anti-infectives and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.

The present invention provides prophylactic an tehrapeutic protocols desinged to prevent, manage, treat, or ameliorate a respiratory condition or one or more symptoms thereof. In particular, the present invention provides methods for preventing, managinge, treating, or ameliorating a respiratory condition or one or symptoms caused by environmental factors or a respiratory infection. The present ivnention encompasses combination therapies, pharamceutical compositions, articles of manufacture, and kits.

An inhalable cold plasma mask device for generation of a breathable cold plasma for delivery to a patient. A biocompatible gas is received in a dielectric barrier discharge (DBD) device that is energized by an electrode that receives energy from a pulsed source. The DBD device can be grounded by a grounding structure. A grounding screen can be used prior to inhalation of the cold plasma. The inhalable cold plasma mask device includes the use of a single-layer or a two-layer approach to its construction. The inhalable cold plasma mask device can have one or two DBD devices. Such a device and associated method can be used to treat upper respiratory tract infections, as well as reducing inflammation, sinus and esophageal polyps in both size and frequency of occurrence.

The invention relates to a lift shaft capable of ventilating by wind power and a lift ventilating method. The lift shaft is provided with a new air pipeline and an air exhausting pipeline. A new air port is arranged corresponding to a position of a floor and the upper part of a lift car. When the lift runs, a lower exhaust blower stops running. A new air shutter in the lift car is started facing to wind based on the running direction. Air flow with ascending air supplying flow and descending air exhausting flow is formed in the internal part of the lift car, so that energy consumption is saved and respiratory tract infection of passengers and bad influence of odor are effectively prevented. The shortcomings that the lift shaft is damp and the lift car is stuffy are overcome. Therefore, the method disclosed by the invention can be widely applied to ventilation of lift shaft and lift car and the lift shaft can be manufactured in an industrial, standard, universal and serial manner. The invention belongs to the fields of buildings, building ventilation and lift manufacturing.

The invention relates to an application of nucleoside analogs in virus resistance. Specifically, the invention relates to the use of nucleoside analogs and pharmaceutical compositions thereof as (a) inhibitors for inhibiting the replication of coronavirus, influenza virus, respiratory syncytial virus, flaviviridae virus, filoviridae virus and/or porcine epidemic diarrhea virus (PEDV); and/or (b) medicines for treating and/or preventing and relieving related diseases caused by infection of coronavirus, influenza virus, respiratory syncytial virus, flaviviridae virus, filoviridae virus and/or porcine epidemic diarrhea virus (PEDV). The nucleoside analogue disclosed by the invention can be used for treating and/or preventing and relieving related diseases such as respiratory tract infection, pneumonia (COVID-19) and the like caused by 2019 novel coronavirus infection.

The present invention relates to pharmaceutical formulations for treating a respiratory tract infection or a pulmonary disease in an individual, comprising a calcium salt and a sodium salt, wherein the ratio of Ca⁺² to Na⁺ is from about 4:1 (mole:mole) to about 16:1 (mole:mole). The invention also relates to methods of treating (including prophylactically treating) and reducing the spread of a respiratory tract infection, methods of treating (including prophylactically treating) a pulmonary disease or an acute exacerbation of a pulmonary disease, and methods of reducing the spread of an acute exacerbation of a pulmonary disease, comprising administering a pharmaceutical formulation that comprises a calcium salt and a sodium salt.

Described are methods of preventing, treating and diagnosing of a subject having a condition, such as, an inflammation or infection of the respiratory tract. Methods of treatment and prevention include administration of effective amounts of calcium salt formulations to a subject. Methods of diagnosing include the use of biomarkers and optionally the use of kits that can detect biomarkers. Further described are methods for modulating an immune response that include the modulation of Toll-like receptors.

The compositions of the present invention comprise a therapeutically effective amount of particles consisting of diphenhydramine or pharmaceutically acceptable salts thereof, optionally in combination with another drug such as pseudoephedrine, or phenylephrine and hydrocodone, in combination with rapidly-dispersing microgranules comprising a disintegrant and a sugar alcohol and/or a saccharide. These compositions are useful in treating the symptoms of one or more diseases or conditions in which diphenhydramine (alone or in combination with one or two other drugs) is a therapeutically effective, e.g. allergic rhinitis, sinusitis, upper respiratory tract infections, motion sickness, Parkinson's disease, insomnia, the common cold, and nighttime pain management, particularly for subjects or patients with dysphagia, and people ‘on the move’.

The invention provides an aqueous pharmaceutical composition for administration as an aerosol to the respiratory tract, nose or oropharyngeal region comprising (i) a macrolide having a poor taste and poor chemical stability in aqueous solution; (ii) at least one salt selected from the group consisting of sodium gluconate, sodium aspartate, sodium acetate, sodium lactate, sodium succinate, sodium maleate, magnesium gluconate, magnesium aspartate, magnesium citrate, magnesium acetate, magnesium lactate, magnesium succinate, and magnesium maleate; or mixtures thereof and (iii) a taste-masking agent different from said salt; wherein (a) the concentration of said macrolide in the composition is in the range of about 0.25 wt.-% to about 15 wt.-%; (b) the molar ratio of said macrolide:said salt is in the range from about 1:0.5 to about 1:100; (c) the pH of the composition is in the range of about 3 to 9; and (d) the osmolality of the composition is in the range of about 150 mOsmol/kg to about 1500 mOsmol/kg. The invention further provides a method of generating an aerosol, preferably by means of a nebuliser, which uses such an aqueous pharmaceutical composition. The macrolide may be used alone or in combination with other drugs. The composition is suitable to treat inflammatory disorders and/or infections of the respiratory tract. It has an improved taste and stability.

Methods for formulating a liposome comprised of a surfactant and a cryopreservative that can be frozen for long term stability, and upon thawing provides an immediate and sustained release delivery profile. Specific liposome formulations include anti-infectives and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.

Methods for treating bacterial respiratory tract infections in an individual comprise administering a therapeutic amount of nitrite composition having a pH of less than 7, and in specific embodiments, a pH of about 5.5-6.5, to the individual. The individual may be a pulmonary disease diagnosed individual and/or the infection may be at least in part caused by mucoid mucA mutant Pseudomonas aeruginosa.

The present invention relates to novel benzimidazole compounds that have useful antiviral activity. More specifically, the invention encompasses benzimidazole compounds that inhibit membrane fusion associated events such as viral transmission, reduce viral load or otherwise treat viral infections. The invention also encompasses the use of benzimidazole compounds as inhibitors of membrane fusion associated events, such as viral transmission. In another embodiment, the invention encompasses processes for making benzimidazole compounds, methods of using the benzimidazole compounds and compositions comprising the benzimidazole compounds. Finally, the invention provides methods for treating, preventing or ameliorating symptoms associated with respiratory infection, particularly that caused by Respiratory Syncytial Virus utilizing the novel benzimidazole compounds of the invention.

Methods for formulating and compositions of immediate and sustained release liposomal products which comprise a surfactant that interacts with liposomes to effect drug release therefrom, and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.

The invention provides a micro-fluidic chip reagent kit for detecting ten respiratory tract infection pathogens and a use method of the reagent kit. The reagent kit adopts a combination of a Taqman probe fluorescent PCR (polymerase chain reaction) technology and a micro-fluidic chip, detects the ten common respiratory tract infection pathogens, can obtain a detection result within 2h, and is highin specificity, and the sensitivity can reach 100 copies/microliter. The kit comprises a sample introduction chamber, at least ten reaction chambers and a micro-fluidic flow channel, wherein the reaction chambers are mutually independent; each reaction chamber is provided with a reagent dry powder for amplifying one respiratory tract pathogen in advance; each reagent dry powder comprises a primerfor amplifying the corresponding respiratory tract pathogen and a TaqMan probe; the reagent dry powder arranged in each reaction chamber in advance can amplify any one of the ten respiratory tract pathogens; the respiratory tract pathogens amplified by the reagent dry powder in all the reaction chambers can include the ten respiratory tract pathogens.

The invention relates to the field of molecular biology detection, in particular to detection of novel coronavirus, influenza A virus and influenza B virus. The invention provides a composition for detecting the viruses, and meanwhile, the invention further provides a kit containing the composition, application of the composition and a method for detecting and typing the viruses causing respiratory tract infection. The composition is combined with a fluorescent probe method, three viruses causing respiratory tract infection can be detected and typed at the same time in one tube, and the composition, the kit and the method have the advantages of being low in cost, high in flux, short in consumed time, easy and convenient to operate and capable of avoiding false positive caused by cross among samples and environmental pollution.

The invention provides a colloidal gold test strip for detecting an IgM antibody. The IgM antibody is a specific IgM antibody for nine respiratory tract infection pathogens, and the colloidal gold test strip comprises a sample pad, a conjugate pad, a nitrocellulose film and a water absorption pad which are attached to a polyvinyl chloride base plate in sequence; the conjugate pad is a glass fiber film wrapped with a rabbit-anti-human IgM antibody-colloidal gold conjugate; the nitrocellulose film is wrapped with 9 detection lines and 1 quality control line in sequence; the 9 detection lines are respectively a mycoplasma pneumoniae recombined antigen, a chlamydia pneumoniae recombined antigen, an influenza a virus antigen, an influenza B virus antigen, a sendai virus antigen, a legionella pneumophila antigen, a Coxiella burnetii antigen, a respiratory syncytial virus antigen and an adenovirus antigen, and the quality control line is a second antibody. The invention further provides a colloidal gold test strip card comprising the colloidal gold test strip and a colloid gold kit, a preparation method of the colloidal gold test strip card, and a method for realizing detection by adopting the colloidal gold test strip, the test strip card or the kit.

Systems and methods for collecting samples from a patient for diagnosis are provided. In many embodiments, the sample collection and analysis system concentrates particles emanating from a patient's cough, sneeze, or breathe in a sample for the diagnosis of a respiratory tract infection or other ailment of the patient. The sample collection and analysis system has a pre-collection assembly (that is patient interface, a collector in fluid communication with a sample reservoir that function in combination to: efficiently capture the volume of air expelled from the subject, direct the expelled air towards a sample reservoir, and separate the desired particle sizes from the expelled air into the sample reservoir.

The invention relates to soluble powder for treating respiratory diseases of poultry, comprising tylosin tartrate, trimethoprim and auxiliary materials. As an antibiotic medicine, the inventive medicament is mainly used to prevent and treat various respiratory tract infections and chronic respiratory diseases of poultry. The tylosin tartrate and the trimethoprim have compatibility when used together. The soluble powder simultaneously acts on different sensitive organisms and mycoplasma, solves the problem of medicament tolerance caused by solely using tylosin to treat, has good absorption and relatively high safety when orally taken.

The invention provides a pathogen inspection reagent, and concretely discloses a primer probe combination and a kit for combined inspection of 15 kinds of respiratory tract infection pathogens. By aiming at specific target sequences of the gene sequence conserved region of klebsiella pneumoniae, haemophilus influenzae, streptococcus pyogenes, staphylococcus aureus, escherichia coli, chlamydia pneumoniae, mycobacterium tuberculosis, stenotrophomonas maltophilia, baumanii, mycoplasma pneumoniae, enterococcus faecalis, ligionella pneumohpillia, streptococcus pneumoniae, bacillus pyocyaneus and mycobacterium abscessus, primers and probes which do not have mutual crossed reaction are designed, so that the problem that detection probes of different pathogens can easily generate mutual influenceor interference is solved; the combination and matching of different primers and probes are ensured; the goal of simultaneously performing efficient specific inspection at the same temperature can also be achieved.